Find out more about Allergan’s presbyopia drop NDA filing

Video

Potential presbyopia treatment coming

Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.

Click here to read this interview's transcript

Click here to listen to this interview's podcast

Recent Videos
Billy R. Hammond details the study, which explored how HEV-light filtering, specifically in the 380-440 nanometer range, impacts visual comfort for patients with presbyopia.
Kurt Moody, OD, FAAO, describes how to fit multifocal contact lenses in a way that patients love
Jacob R. Lang, OD, FAAO
The ins and outs of fitting multifocal contact lenses with Dr Jessica Crooker
Related Content
CORXEL and LENZ Therapeutics release positive topline data on LNZ100 phase 3 trial in China - Image credit: Adobe Stock / ©killykoon

CORXEL and LENZ Therapeutics announce positive topline data from China phase 3 presbyopia trial of LNZ100

Lynda Charters
October 28th 2024
Article
Podcast: Visus presbyopia drop gets FDA IND OK

Podcast: Visus presbyopia drop gets FDA IND OK

Rhett Schiffman, MD, MHSA;Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director;Brooke Henson, Editor
April 9th 2021
Podcast
Orasis Pharmaceuticals secures financing for presbyopia-correcting drops Qlosi - ©frankenphoto

Orasis Pharmaceuticals secures financing for commercial launch of presbyopia-correcting drops

Emily Kaiser Maharjan, Assistant Managing Editor
October 9th 2024
Article
Podcast: Find out more about Allergan’s presbyopia drop NDA filing

Podcast: Find out more about Allergan’s presbyopia drop NDA filing

Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director;Michael Robinson, MD;Brooke Henson, Editor
March 4th 2021
Podcast
Eye drop being administered to petri dish Image credit: AdobeStock/ValeriLuzina

Results released from Ocuphire Pharma of MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis

David Hutton, Managing Editor, Ophthalmology Times
October 4th 2024
Article
Nearsighted office worker looking at computer with glasses Image credit: ©StockPhotoPro - adobe.stock.com

Ocuphire Pharma announces dosing of first patient in phase 3 VEGA-3 clinical trial

Martin David Harp, Associate Editor, Ophthalmology Times
September 5th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.